Search Results

ARS Pharmaceuticals, Inc. announced the closing of its merger with Silverback Therapeutics, Inc.

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) and ARS Pharmaceuticals, Inc. (“ARS”) today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction

Silverback Therapeutics, Inc. announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022.

Silverback Therapeutics, Inc. announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022.

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), today announced that Silverback management will participate in the SVB Leerink 11th Annual Global Healthcare Conference.

Silverback Therapeutics, Inc. announced that Silverback management will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.

Silverback Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy ® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis.

Silverback Therapeutics, Inc. today announced the presentation of preclinical data for SBT8230 at the American Association for the Study of Liver Diseases

Silverback Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, provided an update on strategic priorities and reported financial results for the fourth quarter and full year ended December 31, 2021.